- /
- Supported exchanges
- / BA
- / PFE.BA
Pfizer Inc (PFE BA) stock market data APIs
Pfizer Inc Financial Data Overview
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Pfizer Inc data using free add-ons & libraries
Get Pfizer Inc Fundamental Data
Pfizer Inc Fundamental data includes:
- Net Revenue: 62 785 M
- EBITDA: 24 459 M
- Earnings Per Share: 4 803
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-27
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pfizer Inc News
New
Pfizer and Metsera Reach Deal Expected to Top $10 Billion
Pfizer has agreed to buy the weight-loss drug startup Metsera in a deal that could be worth more than $10 billion, besting Novo Nordisk following a heated bidding war. Under the terms of the cash deal...
Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 Call
On its third-quarter conference call held on Nov. 4, Pfizer PFE shed light on the two topics for which it has been in the news lately — the drug pricing deal with the Trump administration and the ba...
“Pfizer (PFE) Beat The Numbers And People Just Yawned,” Says Jim Cramer
We recently published 10 Stocks Jim Cramer Discussed Including His Palantir Deep Dive. Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently discussed. Pfizer Inc. (NYSE:PFE) reported its t...
LLY's GLP-1 Duo Boosts Sales Amid Rising Demand for Obesity Drugs
Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Despite being on the market for around three years, Mounjaro and Zepbound have b...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.